Regentis Biomaterials Targets $3B Cartilage Repair Market with Cell-Free GelrinC Hydrogel

Regentis Biomaterials (NYSE American: RGNT) is positioning its GelrinC hydrogel as a practical regenerative medicine solution for cartilage damage, potentially addressing the substantial clinical and economic burden of knee osteoarthritis (OA). GelrinC is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing, and higher costs associated with some cell-based therapies.

With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes GelrinC could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The annual U.S. economic burden of knee OA ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000. By intervening early with a regenerative treatment, GelrinC could help delay or prevent the need for more expensive interventions like joint replacement.

GelrinC is based on Regentis’ proprietary Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The hydrogel is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled, synchronous process. As an off-the-shelf product, it eliminates the need for cell harvesting and laboratory processing, simplifying the supply chain and reducing costs.

Regentis is advancing GelrinC toward commercialization, and its single-stage design, proprietary technology, and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health. The company’s focus on orthopedic treatments aligns with the increasing prevalence of knee OA and the need for effective, scalable solutions.

For more information, view the full article at https://ibn.fm/yPKU2. Updates on Regentis Biomaterials are available in the company’s newsroom at https://ibn.fm/RGNT.